G3BP2 and breast carcinoma: Specifically, paclitaxel (PTX) promotes the release of exosomal circBACH1 in breast cancer cells, which contributes to drug resistance by reducing the levels of miR-217 and elevating the expression of GTPase-activating SH3 domain-binding protein 2 (G3BP2) [19].